Evidence suggests that IL24 (also known as MDA‐7) may represent a promising cancer therapeutic agent in further studies,8, 9, 10 while research on IL24 delivery with multiple routes is undergoing continued clinical development (INGN‐241). This evidence concerns the gene IL24 and cancer.